sarcoma, invasive cervical cancer), wasting syndrome OR CD4 <200 (or <15%);thisis largely
historical because ART can reverse CD4 count decline
Seroconversion:Development of
detectable anti-HIV antibodies
Window Period: Time between infection
and development of anti-HIV antibodies:
when serologic tests (ELISA. Wcslern
blot) are negative
All infants born to HIV-infected
mothers have positive enzyme linked
Immunosorbent assay (ELISA) tests
because of circulating maternal anti-HIV
antibodies,which disappear by 18 mo:
early diagnosis is made by detection ol
HIV RNA in plasma
Table 21. Symptomatic Stage (CD4 count thresholds for classic clinical manifestations)
HLAB-S701Testing
Abacavir hypersensitivity reactions
usually only occur in individuals
carrying this HLA allele (
“
5-7% of White
individuals,lower prevalence in other
ethnic groups)
Routine screening for HIA-B'S701at
baseline and definitely prior to abacavir
CD4 Counts Possible Manifestations
<500 cells/mm 3 Often asymptomatic
Constitutionalsymptoms:fever, night sweats,fatigue, weight loss
Mucocutaneous lesions:seborrheic dermatitis. HSV, VZV (shingles),oral hairy leukoplakia (EBV). candidiasis(oral,
esophageal,vaginal). KS
Recurrent bacterial infections,especially pneumonia
Pulmonary and extrapulmonary tuberculosis
lymphoma
Pneumocystnitrorecl pneumonia (formerly PCP)
use
<200 cells/mm'
I.:
Oral thrush
Local and/or disseminated fungal infections:Cryptococcas neofoimans. Coccidioides immitis.Histoplasma capsulatum
Progressive multifocal leukoencephalopathy (PMl)
-JC virus
CHS toxoplasmosis
CMV infection: retinitis, colitis, cholangiopalhy, CNS disease
HIV Status
• CD4 count:progress and stage of
disease
• Viral load:rate of progression
<100 cells/mm*
*50 cclls/mm’
I '
-:
Bacillary angiomatosis (disseminated Bartonella)
Primary CHS lymphoma ( PCNSl)
HIV Non-disclosure Laws in Ontario
In 2017.Ontario changed HIV nondisclosure laws for people living with
HIV.where non-disclosure of HIV
status to a sexual partner Is no longer
considered a criminal offense if one of
the following criteria is met:
• On antiretroviral therapy with a viral
load <200 copies/mL for at least
6 mo
• Viral load between 200-1500 copies/
mland a condom is used properly
and does not break
Laboratory Diagnosis
• anti-HIV antibodies detectable after a median of 3 svk, virtually all by 3 mo (therefore 3 mo window
period)
• initial screening test (3rd generation antibody test): ELISA detects serum antibody to HIV; sensitivity
>99.5%
• increasingly, combination p24 antigen/HIV antibody tests (4th generation) used for screening;
improved sensitivity in early or acute infection and sensitivity/specificity approach 100% for chronic
infection
• confirmatory test:if positive screen, Western blot confirmation by detection of antibodies to at least
two different HIV protein hands (p24, gp41, gpl 20/160);specificity >99.99%
r t
L J
+
Activate Windows
Go to Settings to activate Windows.
ID29 Infectious Disease Toronto Notes 2023
•rapid ( point-of-care) antibody tests: higher false positives, therefore need to confirm positive results
with traditional serology
•p24 antigen: detection by ELISA may be positive during “window period"
r and 2“ prophylaxis may be
discontinued if CD4 count is above
Management of the HIV-Positive Patient threshold for >6 mo while on ART
•verify positive HIV test
•complete baseline history and physical exam, then follow-up every 3-6 mo
•laboratory evaluation
if non-stable and non-suppressed viral load, order routine CD4 count to measure status of the
immune system
I 1 V
Anti Retroviral Pie- Exposure Prophylaxisfor
PiexentiigHIV in High-RiskIndividsals
Cochrane 01Syrst lev 20V2;7:CDOOP189
Purpose: lo evaluate the efficacy of ora etretrowal prophylactic therapy n preietteg HR
efection.
Stidy.Syste-nabc review of 12 recteaiotrc- ed
CrabwiDi S trialsforming the tore aslyss.
Population: 9849 HIV-urrnfected oatetts at»gi
rsx or'
mnCrecting HIV including HSUsnwfcortenf
cooples.and others.
Outcome: New infection with HR.
Results: Daily oral tenofonir disoproiJ f.rjice
(TOP) pi us emtricitabi ne (fit) reduced the rsk of HIV
acquishoc tom pared lo place ho|!I O.ft95t0
028-0.8S). lOf alone also showed sign huut nsh
reduction in trials with fewer patentsft
*
033:951
Q020-0.55).Iherewas no sgnS
adierse Clients in any of the treafreetgetas.Sexual
practces and adherence did not drier between
beacmert and placebo arms.
Conclusions: Pre-exposure prophylais with TOP
nrQ or without fIC effectively reducesthe rsx of
HR acgulsition inhjgh-risk. HR-ucinfeded patents
wr Chou!causing significao!adverse effecs.
• routine HI V-RNA levels (viral load) also important indicator of effect of ART
• baseline HIV resistance testing to guide ARV therapy
• HLA-B'5701 genetic test to screen for abacavir hypersensitivity if considering abacavir in
treatment regimen
CCR5 tropism testing if considering CCR5 antagonist in treatment regi
baseline tuberculin skin test (PPD):induration greater than 5 mm is positive
baseline serologies (hepatitis A, B, and C,syphilis,toxoplasmosis,CMV, VZV)
routine biochemistry and hematology, OCR, urinalysis
annual fasting lipid profile and fasting glucose (due to ART side effects)
•education
:v. r.
• regular follow-up on viral loads (q3-6 mo) as well asstrict adherence to AR T improves prognosis;
routine monitoring of CD4 counts until consistently over 500 cells/uL with suppressed viral load
• prevention of further transmission through safer sex and clean needles for 1DU
• HIV superinfection (transmission of different HIV strainsfrom another H1V+ person) can rarely
occur so barrier protection during sex isstill recommended
discuss importance of disclosing HIV statusto partnersincluding risk of criminal prosecution of
non-disclosure in jurisdictions where applicable
connect to relevant community groups and resources
•health care maintenance
assessment of psychosocial concerns and referral to psychiatry orsocial work if appropriate
• vaccines: influenza annually, 23-valent pneumococcal every 5 yr, HBV (if not immune), HAV (if
seronegative), HPV
annual screening ( PAP smear), regular ST1 screening
• management of comorbid conditions and provision of general primary care
castixtas m
Reasonsfor Deterioration of a Patient
with HIV/AIDS
• Opportunistic infections
• Neoplasms
. Medication-related toxidties
. Co-infections(e.g. HBV. HCVSTIs)
• Non-AIDS-related comorbidities
(e.g.cardiovascular, renal, hepatic,
neurocognitive. bone disease)
Table 22. Prophylaxis Against Opportunistic Infections in HIV-infected Patients
Pathogen Indication for Prophylaxis Preferred Prophylactic Regimen
CD 4 count Pneumocystis jirovecii «200 cells r.r
Toxoplasma gondii
TMP/SMX1SS or DS once daily
IgG antibody to Toxop. IMP.'SMX1 DS once daily '
osrcjand CD4 count
<100 cells/mm1
PPD reaction >5mm or contact with case of INH * pyntome daily x 9 mo
active IB
CD4 count <50 cells/mm5
Mycobacterium tuberculosis
Urcobocterivm avium complex No propbylaxs if patients are started on ARTs
See
SS
from
=
:
USPHS
single
http:/
strength
/
/aidsinfo
IDSA guidelines
.
:
nih
DS
.gov
= double
/
for preventing
strength
opportunistic infections among HIV-infected persons (Re levantSections updated 2013.2015).Available
Treatment
o
Failure
• Assess adherence
• Assess drug Interactions
. Resistance testing
• Rule out opportunistic infections
• Rule out marrow suppression
• Construct new combination drug
regimen
Anti-Retroviral Treatment
Overall Treatment Principles
• recommended that all HIV-positive patients initiate combination ART to restore and preserve
immune function,reduce morbidity, prolong survival,and prevent transmission
• patientsstarting ART should be committed to treatment and understand the importance of
adherence; poor compliance can lead to viral resistance;may defer treatment on the basis of clinical
and psychosocial factors on case-by-case basis
• consider results of baseline resistance testing and complete ART history before initiating or reinitiating ART
• goal: keep viral load below limit of detection i.e. <40 copies/mL (undetectable); viral load should
decrease 10-fold within 4-8 wk, be undetectable by 6 mo, and restore immunological function
• strong evidence against intermittent ART'
or‘
drug holidays’
• patient with undetectable viral load adhering to ART does not transmit HIV to sexual partners
ART Recommendations for Treatment of Naive Patients
• 2 NRTIs + 1 1NSTT or “boosted” PI (combined with ritonavir or cobicistat for improved
pharmacokinetics)
• note:guidelines are subject to frequent change.Combination therapy is suggested, preferably with
single pill regimens
Treatment Failure
• defined primarily by viral load (persistently >200 copies/mL)
• ensure that viral load >40 is not just a transient viremia or ‘blip’; confirm medication adherence,
assess drug interactions, perform resistance testing
r“i
t
_ j
+
Activate Windows
Go to Settings to activate Windows.
ID30 Infectious Disease Toronto Notes 2023
Table 23. Anti-Retroviral Drugs
Class Drugs Mechanism Adverse Effects
Nucleoside reverse abacavir (ABC)
transcriptase inhibitors emtricltabine|FTC)
(hails)
Incorporated into the growing viral DNA Lacbc acidosis (often secondary lo
chain,thereby compettnrely inhibiting mitochondrial toxicity)
lamivudine (3TC) reverse transcriptase and terminating Lipodystrophy
lenofovir disoproxil fumarate (IDF) viral DNA growth
tenofoviralafenamide (TAF)
zidovudine (AZT)
Lactic Acidosis
• Occurs secondary to mitochondrial
toxicity
• Symptoms include abdominal pain,
fatigue,nauseavomiting,muscle
weakness
Bash
Nausea.'
vomiting/diarrhea
Bone marrow suppression (AZT)
Peripheral neuropathy (ddl. d4!)
Orug induced hypersensitivity (ABC)
Pancreatitis (ddl.'dAT)
Myopathy (AZT)
drdanosine (ddl)
stavudme (d41)
Combination Tablets:
AZTilTC (Combivir '
l
AZT/3TC/ABC (Trizivir
*
)
ABC/3TC (Kivexa‘
)
TDFi
'TIC (Truvada'
)
TAF ’FTC (Oescovy :
)
Non-nucleoside reverse delavitdine (DLV)
transcriptase inhibitors doravinne (DOR)
efavirenz (£FZ)
etravirine (ETR)
nevirapine (NVP)
rilphririne (RPV)
Non-competitively inhibit function
of reverse transcriptase,thereby
preventing viral RNA replication
Rash.Stevens-Johnsonsyndrome
CNS:dizziness,insomnia,somnolence,
abnormal dreams (efavirenz)
Hepatotoxicity (nevirapine -avoid
in females with CD4>250.men with
CD4»400)
CYP3A4 interactions
Lipodystrophy,metabolic syndrome
Nausea.1
vomiting/diarrhea
Nephrolithiasis (indinavir)
Rash (APV)
Hyperbilirubinemia (atazanavir.
Indinavir)
CTP3A4 interactions
Hyperlipidemia
Lipodystrophy
Body fat redistribution (mainly with old
ARVs)
• Lipohypertrophy (e.g.dorsal fat
pad.breast enlargement increased
abdominal girth) thought to be
caused primarily by protease
inhibitors
• Lipoatrophy (e.g.facial thinning,
decreased adipose tissue in the
extremities) is thought to be caused
by thymidme analogue NRTIs such as
d4T andAZT
• Metabolic abnormalities:lipids
(ixreased LDL increased TGs).
glucose (insulin resistance.T2DM).
increased risk of CVD
(NNRTIs)
Protease inhibitors
(Pis)’
atazanavir (ATV)
amprenavir (APV)
darunavir (DRV)
darunavi' cobicistat (DRV/c)
Iopinavir.ritonavir (LPV/f)
nelfinavir|NFV)
ritonavir (RTV)
tipranavir (TPV)
indinavir
bictegravir
cabotegravir
dolutegravir (DIG)
ehritegravir (EVG)
raltegravir (RAL)
enfuvirtide (T-20)
Prevent maturation olinfectious
virions by inhibiting the cleavageof
polyproteins
Integrase strand
transfer inhibitors
(INSTIs)
Inhibits integration olHIV DNA mlo the
human genome thus preventingHIV
replication
Fusion inhibitor
(only usedif resistance)
CCR5 antagonist maraviroc (MVC)
Inhibit viral fusion with T-celts by Injection site reactions,rash,
inhibiting gp41.prevelling cell infection infection,diarrhea,nausea,fatigue
Inhibit viralentryby biockung host OCRS Fever,cough,dizziness
co-receptor
'Standard of care ts topharracologically boost most Pis with ritonavir to increase concentrations
Single Tablet ART Regimens
• reduces pill burden and increases adherence
• generally better tolerated
Table 24. Single Tablet ART Regimens
Name Contents Common Side Effects
bictegravirI'emtricitabinehenofovii alafenamide good side effect profile
lenolonr '
emtricilabine/elvilegravirfcobicistal
rilphrirmei'emtricitabineiTenofovir
nlprnrinei'emlricitabineilenofovir alafenamide
elxritegravir.'cobicista(/emIricilabine/tenofovir
dolategraviriabacavir.lamivudine
efamreni'tenofovir.
'
emtricitabine
Biktanry ‘
Genvoya5
Complera:
Odefsey:
Stribild'
Triumeq:
Atripla;
good side effectprofile
good side effectprofile
good side effect profile
good side effect profile
good side effeetprofile use only in HLAB*5701negative patients
psychiatric events,vivid dreams
Recommended ARV Regimens for Treatment-Naive HIV-infected Adults
• initial regimensfor treatment (most include an integrase inhibitor and a pair of NRTTs):
1. bktegravir/TAF/FTC
2.Dolutegravir/ABC/3TC (in patients confirmed to be HLB‘5701 negative)
3.dolutegravir + (TAF or TDF)/(FTC or 3TC)
4.raltegravir + TAF (or TDF)/FTC
5.DTG/3TC
• note: not all regimens are available in all regions
Recommended ARV Regimens for Individuals of Childbearing Potential
• there is an increased risk of neural tube defects in infants born to women on dolutegravir at time of
conception
• it is not known if other INSTIs also increase risk of neural tube defects
• therefore,before beginning an INSTl-containing treatment regimen in individuals of childbearing
potential,the following should be considered:
completing a pregnancy test
• a discussion on risks and benefits of dolutegravir, and lack of information on other INSTIs
« for individuals attempting to conceive:RAL + TDF/FTC,TDF/3TC,or ABC/3FC are preferred
regimens; D IG regimens to be used as an alternative only
• for individuals not attempting to conceive but are sexually active and not using contraception,
consider effectiveness/tolerability, patient preferences in decision
for individuals using effective contraception, treatment approach issimilar to that of individuals
in the general population with HIV
ri
i
_ j
+
Activate Windows
Go to Settings to activate Windows.
ID31 Infectious Disease Toronto Notes 2023
TARGETSITES FOR ANTIRETROVIRAL DRUGS
(A) Fusioninhibitor
IBICCR5 antagonist Early identification of HIV is essential for
patients to receive the maximal benefit
from ART
ICINucleosidereverse transcriptase inhibitors (NRTIsl
(ClNucleotidereverse transcriptase anhibitors
(ClNon-nucleosidereverse transcriptase inhibitors INNRTIs)
101Integrase strand transfer inhibitors (INSTIs)
IEIProteaseinhibitors (Pis)
PROCESS OF Efficacy. Safety, and Elfect on Sexual Behaviour
of On -Demand Pre-Exposure Prophylaxis for HIV
iiMen who have Sex with Men: An Observational
Cohort Study
Lancet HIV 2017:4:402-410
Purpose: Assessthe efficacy,safety,ard effect of
on-demand pre-exposure prophylaxis (Pr(P|on sexual
behaviour.
Methods: Men and transgender women who have
sex with men.previously enrolled in the placebocontrolled ANRSIPERGAU trial. On demandtenofovir
dsopioail fumarate (300 mg) and emlricitabine (200
mg) to be taken before and after sexual intercourse
and participants assessed for incidence of HIV. PrtP
adherence,safety,and sexual behaviour.
Jesuits: if IV incidence was 0.19.'100 person-years
(95% Cl 0.01-1.081 vs.6.60,1100 person-)*
a>s(95%
Cl 3.60-11.05) in the placebo group,relative risk
reduction of 97%. Drug -related 61events were
reported in 14% of participants buiwete sen-limiting.
Parte pants reporting condomlesssexattheir last
receptive anal intercourse increased from 77 to86%
at 18 mo follow-up.
Conclusions:On-demand oral PiEP is highly effective
a1preventing HIV infeebon among high-risk MSM.Ibis
represents an alternative to daily PrEP.
MULTIPLICATION
1.Binding
2.Fusion and uncoating
3 Reverse transcription
4.Integration
5 Translation
6 Assembly and budding
7. Maturation
2 FUSIONAND
UNCOATING
1 BINDING
3.REVERSE
TRANSCRIPTION
^
TRANSLATION
Use of a Vaginal Ring Containing Dapivirine for
HIV-1 Prevention inWomen
HEIM 2016:375:2121-2132
Purpose:Toevaluate whether longer-acting
methods of anti-retroviral therapy (i.e. vaginal rings)
may sim pi ify use of medications an d provide HIV-1
protection.
Methods: Phase 3. randomized, double-blind,
placebo-cnntrolled trial of monthly vaginal ring
containing dapivirine In women (aged 18-45)
,n
Malawi.South Africa, Uganda, and Zimbabwe.
Results: Among 2629women enrolled, tne Incidence
of HIV-1infection was 3.3/100 person-years in
dapivirine group and 4.&T00 person-years in placebo
group.Post hoc analysis identified higher rales of
HIV-1 protection in women >21 yr (56%, 95% Cl 31-71)
but notamong those <21 yr (-27%,95% Cl -133- 311.
which correlated with reduced adherence.
Conclusions: Monthly vaginal ring containing
dapivirine reduced risk of HIV-1infection among
African women.
6.ASSEMBLY AND
BUDDING
7 M A
'
- R A V U '
.
'Stuart Januen 2012
Figure 9. Mechanism of HIV replication
Prevention of HIV Infection
• education, including harm reduction
• safer sexual practices:condomsfor vaginal and anal sex, barriers for oral sex
• harm reduction for 1VDU: avoid sharing needles
prevention of vertical HIV infection:treatment with ART should be initiated prior to pregnancy or
as early as possible during pregnancy.The risk of vertical HIV transmission can be reduced to <1%
if maternal AR T is started in a timely manner and the maternal viral load is undetectable prior to
delivery
• universal blood and body precautionsfor healthcare workers
• post-exposure prophylaxis(PEP) after occupational (e.g. needle-stick injury) and nonoccupational (e.g. consensual sex,sexual assault) exposure to HIV:2- or 3-drug regimen initiated
immediately (<72 h) after exposure and continuing for 4 wk
• recent data has demonstrated efficacy of pre-exposure prophylaxis (oral PrtP or topical microbicides)
in preventing HIV
• ART associated with 96% reduction in risk of transmitting HIV to sexual partners
• screening of blood and organ donation
r ~i
i j
+
Activate Windows
Go to Settings to activate Windows.
ID32 Infectious Disease Toronto Notes 2023
Types of Testing
1. Nominal/Name-Based HIV Testing
• person ordering the test knows the identity of the person being tested for HIV
• HIV test is ordered using the name of the person being tested
• person ordering the test islegally obligated to notify Public Health officialsif test results are positive
for HIV
• test result is recorded in the healthcare record of the person being tested
2. Non-Nominaf Non-Identifying HIV Testing
• similar to nominal/name-based testing on all points except:
• HIV test is ordered using a code or the initials of the person being tested
3. Anonymous Testing
• available atspecialized dinics
• person ordering the HIV test does not know the identity of the person being tested
• HIV test is carried out using a unique non-identifying code that only the person being tested for HIV
knows
• test results are not recorded on the healthcare record of the person being tested
• patient identification and notification of Public Health required to gain access to ART
HIV Pre- and Post-Test Counselling
• a diagnosis of HIV can be overwhelming and is often associated with stigma and discrimination
• consider pre- and post-test counselling, regardless of the results
• goalsinclude: assessing risk,making informed decision to be tested,education to protect themselves
and othersfrom virus exposure,where to go for more information and support
• HIV-positive individualsshould be connected with local supportsendees
FUNGAL INFECTIONS
Skin and Subcutaneous Infections
Superficial Fungal Infections
. see Dermatology. D32,D33,D37,D45D46,and D49
Dermatophytes
• see Dermatology. D31
Subcutaneous Fungal Infections
Etiology
• subcutaneousinoculation by fungi that naturally reside in the soil,including Sporothrix schenckii,
which usually occursin gardeners injured by a rose thorn orsplinter
Clinical Features
• causessubcutaneous nodules at the point of entry,may develop into an ulcer
• fungi may migrate up lymphatic vessels creating nodules along the way -
“nodularlymphangitis”
Treatment
• oral azole
• IV'amphotericin B forsevere or disseminated infection
+
Activate Windows
Go to Settings to activate Window
ID33 Infectious Disease Toronto Notes 2023
Endemic Mycoses
Etiology
• fungal infection that occurs through the inhalation of spores (from soil,bird droppings, vegetation) or
inoculation injury
• thermally dimorphic organisms: mould in cold temperature (e.g.soil),and yeast at higher
temperature (e.g. tissue)
• in North America, the three major endemic mycoses are: histoplasmosis, blastomycosis,and
coccidioidomycosis
Clinical Features
• maybe asymptomatic
• all can cause pneumonia and may disseminate hematogenously
• may reactivate or disseminate during immunocompromised states
Histoplasmosis is commonly associated
with exposure to chicken coops,bird
roosts,and bat caves
Table 25. Endemic Mycoses
Disease Endemic Region Clinical Features Investigations
Histoplosma capsulatum Ohio and Mississippi River Asymptomatic (in most people)
valleys in central USA, Primary pulmonary
Ontario,Ouebec;widespread Fever,cough,chest pain,headache,myalgia,anorexia
CXR (acute):pulmonary infiltrates T hilar lymphadenopathy
CAR (chronic):pulmonary infiltrates,cavitary disease
Disseminated (rate)
Occurs primarily inimmunocompromised patients
Spread to bone marrow (pancytopenia).Gl tract (ulcers),lymph nodes (lymphadenitis),skin,
liver,adrenals, CNS
Blastomycesdermotitidis States east of Mississippi May be asymptomatic
River,Northern Ontario,and Primary:acute or chronic pneumonia
along the Great Lakes Fever,cough,chest pain,chills,night sweats,weight loss
CXR (acute):lobar or segmental pneumonia
CAR (chronic):lobar infiltrates,fthronodular interstitial disease
Disseminated
Spread to skin (verrucous lesions that mimic skin cancer,ulcers,subcutaneous nodules),bones
(osteomyelitis,osteolytic lesions),genitourinary tract (prostatitis,epididymitis)
Primary
"Valley fever":subacute fever,chills,cough,chest pain,sore throat,fabgue that lasts for wk
to mo
Can develop hypersensitivity with arthralgias,erythema nodosum
Disseminated
Rare spread to skin (ulcers),joints (synovitis),bones (lytic lesions),meninges (meningitis)
Common opportunistic infectionin patients with HIV
Fungal culture,fungal stain
Antigen detection (urineand serum)
Serology
Sputum smear and culture
Direct examination of clinical
specimens for characteristic broadbased budding yeast (sputum,tissue,
purulent material)
Cocddioides immitis Deserts in southwest USA.
northwest Mexico
Sputum culture
Direct examination of clinical
specimens forcharacteristicyeast
(sputum,tissue,purulent material)
Opportunistic Fungi
Pneumocystis jirovecii (formerly P. carinii ) Pneumonia:PJP
or PCP
Etiology
• respiratory exposure to unicellular fungi (previously classified as a protozoa)
• can be transmitted from person to person
• without prophylaxis,HIV-positive patients with a CD-I count <200 cells/mm 'have an 80"u lifetime
risk of PIP
• most cases of PJP occur in patients who are unaware of their HIV infection, do not seek medical care
for HIV, or who do not use prophylaxis
• in HIV-negative patients, PJP occurs almost exclusively in immunocompromised patients (e.g.organ
transplant patients,inflammatory conditions,hematological malignancies)
Clinical Features
• symptoms of pneumonia:fever, non-productive cough, progressive dyspnea (and hypoxia)
• classic CXR findings of interstitial pneumonia
• most clinical disease is due to reactivation of latent infection or reinfection by a different genotype in
immunocompromised patients (steroid use,HIV)
Investigations
• CXR: bilateral symmetrical interstitial infiltrates
• ABG:reduced pO:and elevated alveolar-arterial (A-a) gradient
• serum LDH: elevated (>2201U/L)
• induced sputum or lower airway sampling: positive for Pneumocystis, traditional test was
immunofluorescence however many labs using quantitative PCR
CXR inP.provedi
• Bilateral,diffuse opacities
• CXR may be normal (20-30% cases)
• CT shows cysts (hence the name
Pneumocystis) but almost never
pleural effusions
r-i
\
L J
+
Activate Windows
Go to Settings to activate Windows.
ID34 Infectious Disease Toronto Xotes 2023
Treatment and Prevention
• oxygen to keep SaO’ >90%
• antimicrobial options
TMP/SMX (PO or IV) is preferred therapy
dapsone and TMP
• clindamycin and primaquine
pentamidine (IV ) issecond line in severe disease
atovaquone
• corticosteroids used as adjuvant therapv in those with severe hvpoxia ( pO:<70 mmHg or A-a gradient
OB >35 mmHg)
• prophylactic TMP/SMX for those at high-risk of infection (HIV patients when CD4 <200 cells/mm Jor
non-HIV immunocompromised patients under specific conditions)
Cryptococcus spp.
•
Etiology
inhalation of airborne encapsulated yeast from soil contaminated with pigeon droppings(C. O
neoformans) or certain tree speciessuch as Eucalyptus or Douglasfir (C. gatti )
• C. neoformans tends to affect immunocompromised hosts vs.C. gatti which tends to affect
immunocompetent hosts
Clinical Features
• asymptomatic
• pulmonary
• usually asymptomatic or self-limited pneumonitis
only 2% of HIV+ patients present with pulmonary symptomsincluding productive cough, chest
tightness, and fever
• disseminated
frequently disseminatesin HIV+ population
CNS: meningitis(leading cause of meningitis in patientssvith HIV)
skin: umbilicated papules that resemble large lesions of MoDuscum contagiosum
other:bone, lymph nodes,bone marrow,soft tissues, eyes,prostate
Investigations
• serum cryptococcal antigen
• CSF for meningitis:India-ink stain or cryptococcal antigen test, culture to confirm
• lateral flow'cryptococcal antigen assay from serum and CSE
• LP with measurement of opening pressure
Treatment
• in patients with HIV' who have cryptococcal meningitis or severe pulmonary disease:
amphotericin B (+ flucytosine) is used in the first 2 wk for induction therapy;limited duration
due to side effects
• switch to fluconazole for at least 8 wk as consolidation therapy,then continue at lower dose for
prolonged maintenance
serial lumbar puncture or other method of managing increased ICP an important adjunct to
therapy
C. gottii has a limited geographical
distribution including Vancouver Island.
Northern Australia,and Papua New
Guinea
India
o-ink sensitivity for Cryptococcus is
only 50% (higher in HIV patients);now
replaced by cryptococcal antigen test in
most laboratories
Candida albicans a
Etiology
• overgrowth ofC albicans (normally found as part of the microbiome of the skin, mouth, vagina, and
G1 tract)
• risk factors for overgrowth:
immunocompromised state (DM, corticosteroids)
critically ill patients(broad-spectrum antibiotic use, central venous catheters, total parenteral
nutrition)
obesity: maceration and moisture in intertriginous areas, pannus. under breasts
Clinical Features
• mucocutaneous
oral thrush, esophagitis (chest pain, odynophagia), vulvovaginitis (see Gynaecology, GY26),
balanitis, cutaneous (diaper rash,skin folds,folliculitis), chronic mucocutaneous
small satellite lesions beyond the margin of the rash
• invasive
candidemia, endophthalmitis, endocarditis,UTI (upper tract), hepatosplenic disease
n
u
+
Activate Windows
Go to Settingsto activate Windows.
1D35 Infectious Disease Toronto Notes 2023
Treatment
• thrush: clotrimazole troches, miconazole mucoadhesive buccal tablets,or nystatin suspension or
pastilles for mild disease, fluconazole forsevere or refractory disease
• vulvovaginal candidiasis: topical agents (imidazole or nystatin), oral fluconazole for recurrent disease
• cutaneous infection: topical imidazole
• opportunistic infections in HIV'
, other systemic infections:fluconazole or echinocandin
• chronic mucocutaneous: azoles
Aspergillus spp.
Etiology
• infection with Aspergillus fungi ( A. fumigatus, A. flavus) which isfound ubiquitously in the air and
the environment
• Aspergillus produces a toxin called aflatoxin that contaminates nuts, grains, and rice
Clinical Features
• allergic bronchopulmonary aspergillosis (ABPA)
lgE-mediated asthma-type reaction with dyspnea, high fever, and transient pulmonary infiltrates
occurs more frequently in patients with asthma and allergies
• aspergilloma (fungus ball)
ball of hyphae in a pre-existing lung cavity
symptoms range from asymptomatic to massive hemoptysis
CXR:round opacity surrounded by a thin lucent rim of air, often in upperlobes (“air crescent”
sign)
« invasive aspergillosis
associated with prolonged and persistent neutropenia or transplantation
• pneumonia -most common
may disseminate to other organs:brain,skin
severe symptoms with fever,cough, dyspnea, cavitation;fatal if not treated early and aggressively
CXR:local or diffuse infiltrates ± pulmonary infarction, pulmonary nodules with surrounding
ground glass(“halo"sign)
• mycotoxicosis
aflatoxin produced by A.flavus(nuts, grains, rice)
results in liver hemorrhage, necrosis, and hepatocellular carcinoma formation
Treatment Options
• voriconazole or amphotericin B for invasive aspergillosis
• surgical resection for aspergilloma
• corticosteroids ± itraconazole for ABPA
See Undnart InfectittssOsease InaStablefat mare
ieforaatm wfie loricotazolets.aspiotenas Bfar
arasnreaspergrilosstraLIt compared toricotezole
wiBasptofarts Bfor pitman therapjof imras*
aspergikisoPARASITIC INFECTIONS
Protozoa -Intestinal/Genitourinary Infections
Brain abscess 0,
> Ingestion of
]
.marcreevst
Entamoeba histolytica (Amoebiasis)
Etiology
• infection with E.histolytica occurs when the cysts are transmitted via the oral-fecal route in areas of
poor sanitation that have been contaminated by other infected humans,or via sexual activity
• seen in migrants, travellers, institutionalized individuals, Indigenous peoples,MSM
Clinical Features
1. asymptomatic carriers
2. amoebic dysentery
• abdominal pain, cramping, colitis, dysentery, low grade fever with bloody diarrhea secondary’to
local tissue destruction, and ulceration of large intestine
3. amoebic abscesses (liver abscesses,see General and Ihoracic Surgery, GS52)
most common in liver (hematologic spread); presents with right upper quadrant pain, weight loss,
fever, hepatomegaly
• can also occur in lungs and brain
Investigations
• serology, fecal/serum antigen testing, stool microscopic exam (for cysts and trophozoites), colon
biopsy,single stool for multiplex enteric parasite PCR
• E.histolytica indistinguishable microscopically from the non-pathogen E.dispar (distinguish byspecific stool antigen detection or multiplex stool PCR assay)
<g>
1
Lung abscess
Liver abscess
03/
i
lonmotile
cyst i
(infective)
J
4
%trophozoite
Motile +
Inotmlectivel s
Figure10.Entamoeba life cycle
Activate Windows
'
Go to'
Settingstoact
ID36 Infectious Disease Toronto Notes 2023
Treatment and Prevention
• metronidazole
• for invasive disease or cyst elimination:follow with iodoquinol or paromomycin
• aspiration of hepatic abscess if risk of abscess rupture, poor response to medical therapy,or diagnostic
uncertainty
. asymptomatic cystshedding:iodoquinol or paromomycin alone
• good personal hygiene, purification of watersupply by boiling,filtration ( not chlorination )
Giardia lamblia
Etiology
• infection with (i. lamblia occurs via the fecal-oral route with the ingestion of cystsfrom water/food
contaminated by infected humans and other mammals(especially in the Rockies)
• risk factors: travel, camping, institutions,daycare centres, MSM
Clinical Features
• giardiasis (“beaver fever")
symptoms vary from asymptomatic toself-limited mild watery diarrhea to malabsorption
syndrome (chronic giardiasis where the parasite coatsthe small intestine and thus prevents fat
absorption)
nausea,malaise, abdominal cramps,bloating,flatulence,fatigue,weight loss,steatorrhea
no hematochezia (no invasion into intestinal wall),no mucousin stool
Investigations
• multiple stool samples (daily x 3d) for microscopy;single stool for multiplex enteric parasite PCR;
stool antigen used occasionally
• occasionally small bowel aspirate or biopsy
Treatment and Prevention
• metronidazole; nitazoxanide ifsymptomatic
• good personal hygiene and sanitation, water purification (iodine better than chlorination),outbreak
investigation
Trichomonas vaginalis
Etiology
infection with T. vaginalis occurs via sexual contact
Clinical Features
• often asymptomatic (10-50%), especially males(occasionally urethritis,prostatitis)
• Trichomonas vaginitis (see Gynaecology.GY26)
• vaginal discharge (profiise, malodorous, yellow-green or grey,frothy), pruritus,dysuria,dvspareunia
Investigations
• wet mount (motile parasites), antigen detection, culture
• urine PCR to detect in males
Trichomonas causes 2S% of vaginitis
Treatment
• metronidazole for patient and partner(s)
Cryptosporidium spp.
Etiology
• infection with Cryptosporidium spp. via the fecal-oral route occurs with the ingestion of cysts from
water contaminated by infected humans and other animals(including cows)
• risk factors:summer and fall, young children (daycare), MSM, contact with farm animals,
immunodeficiency
Clinical Features
• range from self-limited watery diarrhea (immunocompetent) to chronic,severe, non-bloody
diarrhea with nausea/vomiting, abdominal pain, and anorexia resulting in weight loss and death
(immunocompromised)
Investigations
• modified acid-fast stain ofstoolspecimen,microscopic identification of oocystsin stool or tissue,stool
antigen detection by direct fluorescent antibody,single stool for multiplex enteric parasite PCR
Treatment and Prevention
• supportive care
• in HIV+ patients, (reinitiate ART and try to increase their CD-I count to >100;if fails, try
nitazoxanide or macrolides
• good personal hygiene, water filtration
n
L J
+
Activate Windows
Go to Settings to activate Windows.
ID37 Infectious Disease Toronto Notes 2023
Blood and Tissue Infections
Mtfluquinr lor Prerenting Malaria during Travel
to EndemicArras
Gxhrant Ot Spt ler 2O1);CD0OW91
Purpose losuinmarne efficacy and siletycrf
mefloquine used as propterlastsloi malaria in
trartlltts.
Methods tandomned control Inals|l«elficacgr
and saletrl and noo tandonsiied cohoit studies(lor
saleIf) to compere prophflattie meflciqiune with
placebo, no treatment, or alternathre antimalarlal
agent.
lesnlts: Participants weie mote likeif to discontinue
mefloquine (ft)rs.asouaquoiiepioguaml p%|
due toeditrsf effects (including nausea,vomiting,
abnormal dreams, insomnia, ancetf, and depressed
mood during travel). Do difference in seriousadverse
effects or discontinuation due toedveise effects
wasioond between mefloquine anddoifCfdlne or
mefloquine and cMoroquine.
Conclusions: Absolute ns
*
ol malaria during
short term travel appearslow with mefloqune.
doiftfClme.and atovaguoneprognaml therapy.
Choice ol agent depends on how individual travellers
assessimportance olspecific adverse effects, pill
burden,and cost.
Plasmodium spp. (Malaria)
Etiology
• transmission of Plasmodium spp. ( P. falciparum, P. vivax, P. ovale, P. malariac, P. knowlesi) primarily
occurs during the blood meal of an infected female Anopheles mosquito
• sporozoites injected during the blood meal then infect human liver cells, where they multiply and are
released as merozoites; merozoites infect RBCs and cause disease
• infection with malaria parasites can also occur via vertical transmission (rare) or blood transfusion
• occurs in tropical/subtropical regions (sub-Saharan Africa, Oceania, South Asia,Central America,
Southeast Asia.South America)
Clinical Features
• flu-like prodrome (may include fever, chills, fatigue, diaphoresis, cough, rash, arthralgias, myalgias,
headache,Gl symptoms)
• paroxysms of high spiking fever and shaking chills (due to synchronous systemic lysis of RBCs) that
can last several hours
P. vivax and P. ovale: chills and fever x 48 h but can be variable
P.malariac: chills and fever x 72 h but can be variable
P. falciparum: less predictable fever interval, can be highly variable
• abdominal pain,diarrhea, myalgia, headache, and cough
• hepatosplenomegalv and thrombocytopenia without leukocytosis
• >90% of patients infected with P.falciparum are ill within 30 d
• relapsing malarial attacks may occur after many months due to the reactivation (entering the
erythrocytic cycle) of dormant liver hypnozoites of either P.ovale or P. vivax
• complications:
P.falciparum (most common and most lethal):CNS involvement (cerebral malaria = seizures and
coma),severe anemia,acute kidney injury, ARDS,primarily responsible for fatal disease
P.knowlesi,and rarely P. vivax,can be fatal
Investigations
• CBC screen (assessfor triad of:thrombocytopenia, elevated LDH, and anemia)
• microscopy: blood smearql2-24 h (x3) to rule out infection
thick smear (Giemsa stain) for presence of organisms
thin smear (Giemsa stain)forspecies identification and quantification of parasites
• rapid antigen detection tests
. RCR
$
Malaria isthe most common fatal
infectious disease worldwide
Treatment and Prevention
• allspp. of malaria can lead to severe infection (P. falciparum most likely to cause severe disease and
death)
• markers of severity:clinical features + parasitemia
in any patient with clinical evidence of severe disease: parenteral treatment (artemisinin
combination therapy)
• P. falciparum: most areas of the world show chloroquine resistance - check local resistance patterns
artemisinin combination therapy (e.g. artesunate i doxycydine or artemether-lumefantrine)
atovaquone/proguanil combination (Malarone*)
quinine i doxycydine or clindamycin
• mefloquine and artemisinin resistance increasing in southeast Asia (check local resistance)
• P. vivax, P. ovale: chloroquine (and primaquine to eradicate liver forms)
• P. vivax,chloroquine resistant: atovaquone/proguanil + primaquine or quinine and doxycydine +
primaquine
• P. malariac, P. knowlesi: chloroquine
• prevention with antimalarial prophylaxis (although quality may vary regionally), covering exposed
skin, insecticide-treated bed nets, insect repellent
• prevention of relapse for P. vivax: primaquine or the newly FDA-licensed tafenoquine (in patients £16
y/o who are receiving appropriate antimalarial therapy for acute R vivax infection)
I Sporozoites enter blood via mosquito bile,
inlect iver
l Hepatic infiltration
3 Inlect red blood cells
4 Trophozoite divides asexually many
timesto produce schizont(contains
merozoites)
3 Red blood cell tyses and merozoites
attack other red blood cells(chills and
fever)
6. Male and female gametocytes (from
merozoitesl ingested by mosquito during
bite
7. Male and female gametocytes(from
merozoites)fuse m mosquito gut;
produce ookinete
8. Ookinete matures into an oocystwhich
containsindividualsporozoites;migratesto
mosquito salivary glands
ri
(
_ J
Figure11. Life cycle of Plasmodium
' +
spp.
Activate Windows
Go to Settings to activate Windows.
ID38 Infectious Disease Toronto Notes 2023
Trypanosoma cruzi
Etiology
• found in Mexico,South America,and Central America
• transmission by reduviid insect vector (
“
Kissing Bug"
), which defecates on skin and trypomastigotes
in the stool are rubbed into bite siteorintact mucous membranes by host
trypomastigotes can penetrate intact buccal mucosa when orally inoculated (e.g.via sugar canesweetened unpasteurized juices)
• also transmitted via placental transfer, organ transplantation, blood transfusion,and ingestion of
food or drink contaminated by an infected triatomine
congenital acquisition increasingly recognized as a risk factor for Chagas disease being detected
in non-endemic areas
Clinical Features
• American trypanosomiasis (Chagas disease)
acute:usually asymptomatic,local swelling at site of inoculation (Chagoma) with variable fever,
lymphadenopathy, cardiomegalv,and hepatosplenomegaly
if inoculation via conjunctiva:
“Romana’
ssign:
"
usually unilateral
acute myocarditis, pericardial effusion,meningoencephalitis in severe cases
chronic indeterminate phase:asymptomatic but increasing levels of antibody in blood;most
infected persons(60-70%) remain in this phase, and do not go on to manifest a determinate form
of Chagas disease
chronic determinate:leads to chronic dilated cardiomyopathy,esophagomegaly.and megacolon
10-25 yr after acute infection in 30-40% ofinfected individuals
Investigations
• wet prep and Giemsa stain of thick and thin blood smear,serology, PCR
Treatment and Prevention
• acute: benznidazole or nifurtimox
• indeterminate:increasing trend to treat as acute infection for children and adults under age 50
• chronic determinate:sy mptomatic therapy,surgery as necessary including heart transplant,
esophagectomy, and colectomy; there is unlikely a clinical benefit to antiparasitic treatment at the
determinate stage of disease
• insect control, bed nets
See Landmark Infectious D isessc Trials table lot more
information on the 8MEFIT trial. It details the role
of trypanocidal thera py in patientswith established
Chagas cardiomyopathy.
Classic Triad of Congenital
Toxoplasmosis
• Chorioretinitis
• Hydrocephalus
• Intracranial calcifications
;v.
(required for
completion of
sexual cycle)
Cat \
ingests
mouse Toxoplasma gondii '
.I :
Sheds resistant
oocysts in stool paras te
J
Etiology
• infection with 21 gondii occursthrough exposure to cat feces(oocysts),ingestion of undercooked
meat (tissue cysts),transplacental transmission,organ transplantation,gardening without gloves (cat
oocyst exposure),whole blood transfusions,contaminated watersources
Sporozoites
Mouse
(intermediate host)
Clinical Features Direct ingestion
• (handling kitty congenital
result of acute primary infection of mother during pregnancy (TORCH infection)
stillbirth (rare), chorioretinitis, blindness,seizures,severe developmental delay,microcephaly
• initially asymptomatic infant may develop reactivation of chorioretinitis as adolescent or adultblurred vision,scotoma, ocular pain, photophobia, epiphora, hearing loss, developmental delay
Livestock
(ingestion of poorly
cooked meat!
• acquired
• usually asymptomatic or mononucleosis-like syndrome in immunocompetent patient
infection remainslatent for life unless reactivation due to immunosuppression
• immunocompromised (most commonly AIDS with CD4 <200)
• encephalitis with focal CNS lesionsseen assingle or multiple ring-enhancing masses on CT
(headache and focal neurologicalsigns)
lymph node, liver,spleen enlargement, and pneumonitis
• chorioretinitis
Investigations
• serology, CSF Wright-Giemsa stain, antigen or DNA detection ( PCR); pathology provides definitive
diagnosis
• immunocompromised patients: considerCT scan ( ring-enhancing lesion in cortex or deep nuclei) and
ophthalmologic examination
Treatment and Prevention
• no treatment if:immunocompetent, not pregnant,no severe organ damage
• immunocompromised: pyrimethamine + sulfadiazine + folinic acid
• pregnancy:spiramycin if fetal status unknown, pyrimethamine + sulfadiazine + folinic acid if
confirmed or highly suspected fetal infection, avoid undercooked meat and refrain from emptying cat
litter boxes
. HIV:TMP/SMX
• proper hand hygiene, cook meat thoroughly to proper temperature
n
u
Figure12. Life cycle of Toxoplasma
gondii
+
1/3 of Ontario's population is infected
with Toxoplasmagondii
Activate Windows
Goto Settingsto activate Windows.
ID39 Infectious Disease Toronto Notes 2023
Helminths =
E
Roundworms - Nematodes ©
Table 26. Nematodes (Roundworms) l
T
Nematode Epidemiology Transmission Clinical Presentation Treatment
Human feces,ingestion Often asymptomatic,abdominal
discomfort
Heavy infections may cause
intestinal blockage,growth
Impairment
Cough,dyspnea,pulmonary
infiltrates from larval migration
through lungs (Loffler's syndrome)
Diarrhea|
*
mucous,blood),
abdominal pain,rectal prolapse,
stunted growth
River blindness (onchocerciasis). Ivermectin * doiycydine
dermatitis
Mebendazole OR
albendazole OR
pyrantel pamoate OR
ivermectin
to: :e ~:st
common in tropical and of contaminated food
Ascaris
lumbricoides
or water containing
eggs
subtropical areas)
Trichuris
trichiura
(whipworn)
Onchocerca
volvulus
Wuchererio
boncrolti
Ingestion of eggs
in soil
Worldwide (most Mebendazole OR albendazole
common in tropical
areas)
Sub-Saharan Africa.
Latin America
Tropics
Blackfly bite
Mosquito bite Oamage to lymphatics causes Diethylcarbamazine * doiycydine
lymphadenopathy.lymphedema,
lymphatic filariasis (elephantiasis),
hydrocele
Tropical pulmonary eosinophilia
loiasis is mostly asymptomatic. Surgicalremoval of adult worms,
Symptomscan include episodic diethyrlcarbamazme.albendazole
angioedema (Calabar swellings)
and subconjunctival migration
resulting in eye pain and ifching
1. Embryonated eggs ingestedbytunns
2 Larvae hatchinsmall intestine
3. Females migrate out anus at night
West and Central
African rainforest (e.g.
Cameroon.Central
African Republic)
Loo loo Deerfly bite
Figure 13. Life cycle of Enterobius
Enterobius
vermiculoris
(pinworm)
Human host:fecal-oral Asymptomatic earners or severe
self-inoculation and
fomiteperson-to- ani)
person transfer
Adult worms live in
Sticky tape test eggs adhere to tape
nocturnal peri-anal itching (pruritus applied toperianal skin (need S-7
tests to rule out)
Eiammabon of perianal skin at night
may revealadult worms
Usually no eosinophilia as no tissue
invasion
Mebendazole,albendazole;pyrantel
inpregnancy
Change underwear,bathe in
morning,pajamas to bed.wash
hands,trim fingernails
Treatall family members
simultaneously
Reinfection common
Worldwide
Occasional vaginitis,ectopic
migration to appendix or other
cecum and deposit pelvic organs
eggs in peri-anal skin Abdominal pain,nauseaVomiting
withhigh worm burden
Strongytoides
stercorolis
(threadworm)
Subtropical,tropical. Fecal contamination ol One of few worms able tomultiply
and temperate soil:transmission via in human host
(mclud ng southern US) unbroken skin,walking Mostly asymptomatic infection or
can have pruritic dermatitis at site
of larval penetration
Transient pulmonary symptoms
during pulmonary migration of
larvae|eosinophilicpneumonrtis ^
Loffler's syndrome)
Abdominal pain,diarrhea,pruritus
ani.larva currens (itchy rash)
Hyperinfection:occasionalfatal
cases caused bymassive autoinfection in immunocompromised
host;immunoablative therapy,
including high-dose corticosteroids,
is the most common risk factor for
disseminated infection
Ivermectin anchor albendazole
barefoot
Autoinfection:
penetration of larvae
through Gl mucosa or
perianal skin
Adult worms live
in mucosa of small
intestine
vv-v
^
'
V© V
1. Larvae penetrate intact skin of host
2.Larvae migrate to lungs via
bloodstream
3. Larvae crawl up trachea and down to
Gl tract (cough/swallow)
4.Adult worms in intestine
5.Eggs produced in bowel
6.Larvae
7.Bowel movement containing larvae
Figure 14. Life cycle of Strongyloides
r ~i
L J
+
Activate Windows
Go to Settings to activate Windows.
ID10 Infectious Disease Toronto Notes 2023
Flatworms- Cestodes/Trematode
Table 27. Cestodes/Trematodes (Flatworms)
Epidemiology Transmission Clinical Presentation Treatment
CEST00ES
Taeniasolium
( pork tapeworm}
Corticosteroids albendazole * praziquantel for most
cysticercosis
Antiepileptics if seizures
Praziquantel for adult tapeworm in gut (taeniasis)
Praziquantel
Worldwide,but more common Undercooked pork (larvae), Taeniasis:mild Gl symptoms
in places with poor sanitation human leces(eggs} Cysticercosis: masslesions in CNS.eyes,skin,seizures
Taeniasaginota Worldwide,but more common Undercooked beef (larvae) Taeniasis: mild Gl symptoms
(bed tapeworm) wherever contaminated raw
beelis eaten
Diphyllobothrium Europe. North America, Asia Raw fish
latum
Ichinocoecus
granulosus
Vitamin Bit deficiency leading to macrocytic anemia and Praziquantel
posterior column deficits
Liver/lung cysts (enlarge between 1-20 yr; may cause
mass effect or rupture)
Risk ol anaphylaxis if cystic lluid released during surgical Percutaneous aspiration * perioperative albendazole
evacuation
Rural areas.sheep- raising
countries
Dog feces (eggs) Albendazole t praziquantel alone
Surgery » perioperative albendazole
TREMATODES
Japan,Taiwan.China.
Southeast Asia
Schistosoma spp. Africa,Southeast Asia,focal In Fresh water exposure
Western Hemisphere
Raw fish Exists In bile ducts, causes inflammation and sometimes Praziquantel
cholanglocardnoina
Chronic sequelae secondary lo long term infection|c.g. Praziquantel
chronic liver disease, squamous cell carcinoma|SCC) ol
the bladder)
Clonorchis
sinensis
Schistosoma spp.
Etiology
infection with Schistosoma spp. (S. niattsonl,.S'
, hcniatobitim, S. iaponicum) occurs following
penetration of unbroken skin by their larvae (cercariae) which are found in infested fresh water
• adult worms live in terminal venules of bladder/bowel passing eggs into urine/stool
• schistosomes cannot multiply in or pass between humans
• more common in individuals from sub-Saharan Africa,South America, Asia,Caribbean, Eastern
Mediterranean /North Africa
Clinical Features
• most asymptomatic;symptoms seen in travellers ( nonimmune)
• swimmer’s itch: pruritic skin rash at site of penetration (cercarial dermatitis)
• acute schistosomiasis (Katayama fever): hypersensitivity to migrating parasites (4-8 wk after
infection)
fever, hives, headache, weight loss, cough, abdominal pain, chronic diarrhea, high-grade
eosinophilia
• chronic schistosomiasis (can persist for years):
S. mattsoni, S. japonicum
• worms in mesenteric vein, eggs in portal tracts of liver and bowel
heavy infections: intestinal polyps, portal and pulmonary HIN,splenomegaly (2° to portal HTN ),
hepatomegaly
S. hcinatobiiiiii
T . Eggs released into water
2. Snail (intermediate host)
releases infective larvae
3. Infective cercariae
4 Penetrate skin
5 Migrate to portal
blood stream;
mature in liver
6. Migrate to
Gl and GU
- worms in vesical plexus, eggs in distal ureter and bladder induce granulomas and
fibrosis
- hematuria and obstructive uropathy; associated with squamous cell bladder cancer
neurologic complications:spinal cord neuroschistosomiasis (transverse myelitis), cerebral or
cerebellar neuroschistosomiasis (increased ICP, focal CNS signs,seizures)
pulmonary complications: granulomatous pulmonary endarteritis, pulmonary H TN, cor
pulmonale; especially in patients with hepatosplenic involvement
Investigations
• serology (high sensitivity and specificity), CBC (eosinophilia, anemia, thrombocytopenia), loopmediated isothermal amplification, circulating serum antigen test
• S. mansoni, S. japonicum: eggs in stool,liver U/S shows peri-portal fibrosis,rectal biopsy
• S.hematobium: bladder biopsy, eggs in urine and occasionally stool, kidney and bladder U/S
Treatment and Prevention
• praziquantel
• add prednisone if acute schistosomiasis or neurologic complications develop
• proper disposal of human waste, molluscicide (pesticide against molluscs), avoidance of infested fresh
water while travelling
r-»
No comments:
Post a Comment
اكتب تعليق حول الموضوع